Vimta Labs Limited has informed the Exchange regarding the Amendment to AOA/MOA of the company.
VIMTALABS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
At the 35th Annual General Meeting held on June 6, 2025, shareholders of Vimta Labs approved two key items. First, the company added new objects to its Memorandum of Association (MOA) to expand into Contract Research and Development (CDMO) activities covering drug discovery, biotechnology, pharmaceuticals, biopharmaceuticals, and life sciences. A second new clause enables research and development of biologics, biosimilars, peptides, and complex generics, including product formulation and packaging. Second, shareholders approved a revision in remuneration for three existing executive directors: Managing Director Harita Vasireddi, Executive Director (Operations) Harriman Vungal, and Executive Director Satya Sreenivas Neerukonda. No new appointments or resignations were disclosed in this filing.
The MOA expansion signals a strategic push by Vimta Labs into higher-value CDMO and biologics/biosimilars segments, which could open new revenue streams. The revised pay for the existing promoter-family executive team aligns incentives with this growth push, though it also raises ongoing cost commitments for shareholders.